Track topics on Twitter Track topics that are important to you
Eribulin mesylate (Halaven; Eisai) - a synthetic analogue of the marine natural product halichondrin B that interferes with microtubule dynamics - was approved in November 2010 by the US Food and Drug Administration for the treatment of metastatic breast cancer.
Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
This article was published in the following journal.
Name: Nature reviews. Drug discovery
ABSTRACT Aim: This multicenter study describes the effectiveness of eribulin in current practice. Patients & methods: In total, 78 patients with advanced metastatic breast cancer, previously treate...
To discuss treatment with eribulin in clinical practice outside a clinical trial.
Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was app...
Background:We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity of a combination eribulin and S-1 therapeu...
To investigate the effect of treatment with resveratrol combined with imatinib mesylate on human chronic myelogenous leukemia K562 cell growth inhibition and apoptosis, in vitro cultured human chronic...
This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refrac...
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in...
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval a...
This pilot trial studies the concentration of eribulin mesylate in the brain of patients with breast, bladder, or non-small cell lung cancer that has spread to the brain (metastases). Drug...
This phase I/II trial studies the side effects and best dose of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby ...
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.